November 12, 2012 15:08
FAS green-lights AFK Sistema bid to buy 100% of VeroPharm, but with terms (Part 2)
MOSCOW. Nov 12 (Interfax) - Russia's Federal Antimonopoly Service (FAS) has approved AFK Sistema's (RTS: AFKS) request for permission to buy 100% of the stock in pharmaceuticals company OJSC VeroPharm (RTS: VRPH), but has attached some terms, a FAS statement says.
The FAS established that VeroPharm has a dominating position on the market for medicines with MNN Gemifloksatsin, and its subsidiary LLC LENS-Pharm with MNN Poliadenilovaya Kislota + Poliuridilovaya Kislota.
The FAS takes the view that the conduct of this deal could lead to a limiting of access to the market for the sale of these medical preparations by independent counteragent VeroPharm and LENS-Pharm. In light of this, the FAS requires of Sistema and VeroPharm to ensure the fulfillment of all contracts for the delivery of all medicines existing on the date the deal is completed.
Before the deal is done, Sistema is to post on its official website the document regulating its commercial policy as regards VeroPharm medical preparations, and announce changes to commercial policy in letter form to the FAS within thirty days.
The parties are not to, from the date the deal is completed, effect any unfounded economic or technological reduction or halt of the production and supply of goods that are still in demand. They are also to announce to the FAS either of such circumstances in letter form within thirty days.
AFK Sistema and VeroPharm are to annually inform the FAS in letter form that they are meeting these conditions.
The parties to the deal are to announce its completion to the anti-monopoly agency within twenty days from the day the deal is wrapped up.
According to DSM Group data, VeroPharm is third in a rating of the largest Russian pharmaceutical companies. Company product is provided by three plants: in Belgorod, Voronezh, and Pokrov. VeroPharm specializes in the production of Rx medical goods, which account for about 70% of its sales revenues.
Pharmacy Chain 36.6 (RTS: APTK) owns 51.8% of the company.
(Our editorial staff can be reached at firstname.lastname@example.org)
March 27, 2015
LAVROV, KERRY DISCUSS IRAN NUCLEAR PROGRAM DEAL, AGREE ON POSSIBILITY TO HOLD MEETING BETWEEN P5+1 FOREIGN POLICY CHIEFS, IRAN IN LAUSANNE ON MARCH 29
OSCE mission: Half of homes in Shyrokyne destroyed, others damaged
Suspected killer of Ukrainian Security Service officer detained - Poroshenko
Moscow sees release of nearly 700 prisoners in Syria as sign of intention to reach political settlement
DPR tells OSCE it will hold military exercises
OSCE monitors hear 133 explosions during visit to Donetsk airport - report
Ukraine accuses militia forces of multiple ceasefire breaches
Two militiamen's bodies swapped for 22 dead Ukrainian soldiers - spokeswoman
Russian MICEX stock index falls to lowest level since Jan 20
No grounds for Kremlin's new judgments about implementation of Minsk agreements - spokesman
OSCE monitors confirm ceasefire breaches by Kyiv - Russian envoy
Main indexes of the Russia stock market for March 27
Central Bank to raise forex auction rates from March 30